Editorial Comment to Activity of axitinib in patients with metastatic renal cell carcinoma previously treated with both vascular endothelial growth factor receptor tyrosine-kinase inhibitor and mammalian target of rapamycin inhibitor

Yoshihiro Wada

doi:10.1111/iju.12423

Editorial Comment to Activity of axitinib in patients with metastatic renal cell carcinoma previously treated with both vascular endothelial growth factor receptor tyrosine-kinase inhibitor and mammalian target of rapamycin inhibitor

International Journal of Urology ◽

10.1111/iju.12423 ◽

2014 ◽

Vol 21 (7) ◽

pp. 741-741

Author(s):

Yoshihiro Wada

Keyword(s):

Renal Cell Carcinoma ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Mammalian Target Of Rapamycin ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Previously Treated ◽

Endothelial Growth Factor

Get full-text (via PubEx)

Activity of axitinib in patients with metastatic renal cell carcinoma previously treated with both vascular endothelial growth factor receptor tyrosine-kinase inhibitor and mammalian target of rapamycin inhibitor

International Journal of Urology ◽

10.1111/iju.12414 ◽

2014 ◽

Vol 21 (7) ◽

pp. 740-740 ◽

Cited By ~ 1

Author(s):

Ryuichi Mizuno ◽

Akira Miyajima ◽

Mototsugu Oya

Keyword(s):

Renal Cell Carcinoma ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Mammalian Target Of Rapamycin ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Previously Treated ◽

Endothelial Growth Factor

Get full-text (via PubEx)

Everolimus in Patients with Metastatic Renal Cell Carcinoma Who Progress after Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFR-TKI) Therapy: UK Results from the react Trial on Behalf of the UK React Investigators

Annals of Oncology ◽

10.1016/s0923-7534(20)33390-1 ◽

2012 ◽

Vol 23 ◽

pp. ix271-ix272

Author(s):

S. Chowdhury ◽

J. Larkin

Keyword(s):

Renal Cell Carcinoma ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Receptor Tyrosine Kinase ◽

Renal Cell ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

The Uk ◽

Endothelial Growth Factor

Get full-text (via PubEx)

Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study

European Journal of Cancer ◽

10.1016/j.ejca.2011.11.027 ◽

2012 ◽

Vol 48 (3) ◽

pp. 333-339 ◽

Cited By ~ 86

Author(s):

E. Calvo ◽

B. Escudier ◽

R.J. Motzer ◽

S. Oudard ◽

T.E. Hutson ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Receptor Tyrosine Kinase ◽

Subgroup Analysis ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Phase Iii ◽

Vascular Endothelial ◽

Endothelial Growth Factor

Get full-text (via PubEx)

Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial

Frontiers in Oncology ◽

10.3389/fonc.2020.00664 ◽

2020 ◽

Vol 10 ◽

Cited By ~ 1

Author(s):

Jianhui Ma ◽

Yan Song ◽

Jianzhong Shou ◽

Yuxian Bai ◽

Hanzhong Li ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Vascular Endothelial Growth Factor ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Phase 2 ◽

Phase 2 Trial ◽

Previously Treated ◽

Endothelial Growth Factor

Get full-text (via PubEx)

Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-015-2725-8 ◽

2015 ◽

Vol 75 (5) ◽

pp. 1025-1035 ◽

Cited By ~ 5

Author(s):

Inkeun Park ◽

Jae-Lyun Lee ◽

Jin-Hee Ahn ◽

Dae-Ho Lee ◽

Kyoo-Hyung Lee ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Treatment Failure ◽

Receptor Tyrosine Kinase ◽

Mtor Inhibitor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Endothelial Growth Factor

Get full-text (via PubEx)

Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World

Anticancer Research ◽

10.21873/anticanres.14730 ◽

2020 ◽

Vol 40 (12) ◽

pp. 7037-7043

Author(s):

VITTORIO GEBBIA ◽

ANDREA GIRLANDO ◽

ALFIO DI GRAZIA ◽

IVAN FAZIO ◽

NICOLÒ BORSELLINO ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Receptor Tyrosine Kinase ◽

Real World ◽

Stereotactic Radiotherapy ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Endothelial Growth Factor

Get full-text (via PubEx)

Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor–tyrosine kinase inhibitor (VEGFr-TKI) therapy.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.4601 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 4601-4601

Author(s):

V. Grünwald ◽

P. I. Karakiewicz ◽

S. E. Bavbek ◽

K. Miller ◽

J. H. Machiels ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Expanded Access Program ◽

Endothelial Growth Factor ◽

Access Program

Get full-text (via PubEx)

Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following Treatment Failure with a Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor

Cancer Research and Treatment ◽

10.4143/crt.2013.154 ◽

2014 ◽

Vol 46 (4) ◽

pp. 339-347 ◽

Cited By ~ 2

Author(s):

Kwonoh Park ◽

Jae-Lyun Lee ◽

Jin-Hee Ahn ◽

Kyoo Hyung Lee ◽

In-Gab Jeong ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Treatment Failure ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Efficacy And Safety ◽

Endothelial Growth Factor

Get full-text (via PubEx)

Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study

Onkologie ◽

10.1159/000348522 ◽

2013 ◽

Vol 36 (3) ◽

pp. 95-100 ◽

Cited By ~ 13

Author(s):

Lothar Bergmann ◽

Peter J. Goebell ◽

Ulrich Kube ◽

Manfred Kindler ◽

Edwin Herrmann ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Receptor Tyrosine Kinase ◽

Interim Analysis ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Interventional Study ◽

Endothelial Growth Factor

Get full-text (via PubEx)

Retrospective Study of Bleeding Risk with Concomitant Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor and Anticoagulation

The Oncologist ◽

10.1002/onco.13897 ◽

2021 ◽

Author(s):

Akhilesh Sivakumar ◽

Sarah E. Caulfield ◽

Chao Zhang ◽

Subir Goyal ◽

Mehmet A. Bilen ◽

...

Keyword(s):

Vascular Endothelial Growth Factor ◽

Retrospective Study ◽

Growth Factor ◽

Tyrosine Kinase Inhibitor ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Bleeding Risk ◽

Vascular Endothelial ◽

Endothelial Growth Factor

Get full-text (via PubEx)